Table 2.

Univariate survival analysis of OS and DFS in 113 patients with endometrial carcinoma

Variables	n	OS			DFS
		Mean ± SE (mo)	95% CI	P a	Mean ± SE (mo)	95% CI	P a
Age (y)
<60	49	69 ± 2	65‐73	0.748	69 ± 2	64‐73	0.880
≥60	64	66 ± 2	63‐70		67 ± 1	64‐70
Histological cell type
Endometrioid	100	70 ± 1	67‐72	0.138	70 ± 1	67‐73	0.068
Nonendometrioid	13	62 ± 5	53‐72		63 ± 4	54‐71
FIGO stage
Ⅰ	77	72 ± 1	69‐74	0.003	71 ± 1	69‐74	0.002
Ⅱ	15	65 ± 4	57‐74		68 ± 2	64‐73
Ⅲ	17	63 ± 4	54‐71		64 ± 4	56‐71
Ⅳ	4	37 ± 15	8‐66		37 ± 15	8‐66
Histological grade
G1	43	72 ± 1	70‐74	0.459	73 ± 1	71‐75	0.291
G2	41	65 ± 2	60‐70		64 ± 3	58‐69
G3	29	62 ± 3	55‐69
Lymph node metastasis
No	104	70 ± 1	68‐73	0.019	70 ± 1	68‐73	0.012
Yes	9	55 ± 8	38‐71		53 ± 9	35‐70
Depth of myometrial invasion
<50%	57	70 ± 1	68‐71	0.007	70 ± 1	69‐72	0.002
≥50%	56	65 ± 3	60‐70		65 ± 3	59‐70
HPIP
Low expression	54	73 ± 1	72‐75	0.002	73 ± 1	71‐75	0.002
High expression	59	63 ± 2	58‐68		61 ± 3	56‐67

Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; HPIP, hematopoietic pre‐B‐cell leukemia transcription factor‐interacting protein; OS, overall survival; DFS, disease‐free survival.

^aLog‐rank test.